Intellia Therapeutics On March 19, Notified Regeneron Pharmaceuticals That Co Is Opting Out Of Its Factor IX Co-Development And Co-Funding Agreement
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics has informed Regeneron Pharmaceuticals of its decision to opt out of the co-development and co-funding agreement for Factor IX, according to an SEC filing.
March 22, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Intellia Therapeutics opts out of its agreement with Regeneron Pharmaceuticals for Factor IX co-development and co-funding.
The decision to opt out of the co-development agreement may have mixed impacts on Intellia's stock. On one hand, it could free up resources for other projects. On the other, it might raise concerns about the company's pipeline and strategic direction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
NEUTRAL IMPACT
Regeneron Pharmaceuticals receives notice from Intellia Therapeutics about opting out of the Factor IX co-development and co-funding agreement.
The impact on Regeneron Pharmaceuticals is uncertain. While losing a partner in co-development could be seen negatively, Regeneron's diverse portfolio and strong research capabilities may mitigate any potential negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80